When will Compass Pathways submit a NDA for COMP360 psilocybin? (COMP360 psilocybin - NDA)
98%before December
- before December98%▲ 6
- before 202798%▲ 5
- before April 202798%
Install
When will Beam Therapeutics submit a BLA for Risto-cel?
The odds
93%before April 2027
- before April 202793%▲ 15
- before 202756%▼ 1
- before December14%
How the odds have moved
before April 2027: 73% on Oct 20, 93% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Why it moved
- Nov 9, 6 PM ETbefore April 2027: 78% → 93%
No headline about it in the hours around this move.
The biggest swings over the chart's period, each with the headlines about the market's subject published in the hours before it. News and odds moving together is not proof one caused the other.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| before April 2027 | 93% | ▲ 15 | 29¢ | $1.08 | 3.4K | |
| before 2027 | 56% | ▼ 1 | 53¢ | 60¢ | $1.67 | 1.7K |
| before December | 14% | 12¢ | 16¢ | $6.25 | 5.0K | |
| before November | 6% | ▲ 4 | $16.67 | 2.8K | ||
| before October | 2% | $50.00 | 9.5K | |||
| before September | 1% | $100.00 | 7.5K |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: Beam Therapeutics, Risto-cel, Ristoglogene
Search ›- Head-To-Head Contrast: Beam Therapeutics (NASDAQ:BEAM) & Novavax (NASDAQ:NVAX)Posted by Tristan Rich on Oct 25th, 2026 Beam Therapeutics (NASDAQ:BEAM – Get Free Report) and Novavax (NASDAQ:NVAX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies…
- Verve TherapeuticsEli Lilly is acquiring Beam Therapeutics’ opt-in rights to three Verve Therapeutics gene-editing therapies for cardiovascular conditions. The deal comes four months after the pharmaceutical giant began a partnership on a preclinical Verve…
- Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech WatchlistBiotech stocks enter the week following strong gains, with investor attention turning to Eli Lilly and Merck’s earnings, Oruka Therapeutics’ psoriasis readout and three approaching FDA deadlines. Healthcare and biotech stocks outperformed…
- Insider Selling: Beam Therapeutics (NASDAQ:BEAM) CEO Sells $589,250.00 in StockCheck Out Our Latest Stock Analysis on Beam Therapeutics Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both…
- Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exercisePosted by Defense World Staff on Oct 19th, 2026 Beam Therapeutics Inc. (NASDAQ: BEAM) chief executive and director John M. Evans sold 50,000 shares from 2026-10-15 to 2026-10-16 at $23.57 to $23.98 each. The Form 4 says the shares were…
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Cathie Wood, the CEO and founder of Ark Investment Management, owns, through her various Ark ETFs, $220.4 million in Beam Therapeutics (NASDAQ: BEAM) shares. It is a healthcare company that focuses on gene editing to develop precision…
- Signet Jewelers (NYSE:SIG) Insider Sells $191,400.00 in StockStash Ptak also recently made the following trade(s): SIG opened at $118.18 on Monday. The firm has a market cap of $4.53 billion, a P/E ratio of 13.61, a PEG ratio of 0.65 and a beta of 1.10. The business’s fifty day simple moving average…
- Beam Therapeutics CEO Evans sells 50,000 sharesAfter $1.03 option exercises, Beam Therapeutics (BEAM) CEO sells 50,000 shares under a trading plan. Stock Titan - [Form 4] Beam Therapeutics Inc. Insider Trading Activity Beam Therapeutics CEO Evans sells 50,000 shares The trading plan…
- Beam Therapeutics' Evans proposes $600K share saleAfter a $589K sale, John M. Evans proposes selling 25,000 Beam Therapeutics (BEAM) shares. Stock Titan Beam Therapeutics' Evans proposes $600K share sale The notice lists the shares as obtained through a stock option exercise from the…
- IBD Data Stories | Page 88 of 769 | Investor's Business DailyBREAKING: Futures Rise With Meta, SpaceX, Tesla Earnings Ahead Find out which top-rated stocks have just earned a spot on IBD’s lists of the best growth stocks. Freeport McMoRan saw its IBD SmartSelect Composite Rating rise to 97 Monday…
- Cathie Wood Just Sold $3.36M in META Stock. Here’s What She Bought InsteadOn Monday, Cathie Wood’s ARK Invest sold 4,520 shares of Meta Platforms (META) through its ARK Innovation ETF (ARKK). Based on Meta’s closing price of $742.96, the sale was worth an estimated $3.36 million. The move came after ARK Invest…
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPR Newswire NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Beam Therapeutics Inc. ("Beam" or the "Company") (NASDAQ: BEAM). Such investors are advised to contact Danielle Peyton at…
Related markets
All fda & drugs ›Will the FDA approve retatrutide? (retatrutide (LY3437943))
Dec 9, 2027even chance by
- Before Jan 1, 20272%
- Before Jul 1, 202712%▼ 9
- Before Jan 1, 202856%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance▼ 1
When will the FDA reclassify BPC-157 to Category 1?
10%Before 2027
- Before 202710%▲ 1
When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
90%Before 2028
- Before 202890%▼ 1
- Before October 202788%▼ 1
- Before July 202787%
2 more
- Before Mar 1, 202765%▼ 1
- Before Jan 1, 202719%▲ 2
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
74%chance▼ 1
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Progressives. Prices read from the venues 2 min ago. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Progressives, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Progressives index; prices of stocks, rates and coins from 4Progressives Finance. Nothing here is betting, financial or investment advice. Terms of use. How to use Predictions